Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors-Reference-Cited by-同舟云学术

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type‐5 inhibitors

Published:2020-01 Issue:1 Volume:10 Page:1-11
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Frantz Robert P.¹,Hill Jerrold W.²,Lickert Cassandra A.³,Wade Rolin L.²,Cole Michele R.³,Tsang Yuen³,Drake William³

Affiliation:

1. Department of Cardiovascular DiseasesMayo ClinicRochesterUSA

2. IQVIAPlymouth MeetingUSA

3. Actelion Pharmaceuticals US, Inc.South San FranciscoUSA

Funder

Actelion Pharmaceuticals

Actelion Pharmaceuticals US, Inc.

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894019880086

Reference37 articles.

1. Pulmonary arterial hypertension‐related morbidity is prognostic for mortality;McLaughlin VV;J Am Coll Cardiol,2018

2. Evaluation of the predictive value of a clinical worsening definition using 2‐year outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis;Frost AE;Chest,2013

3. The prognostic impact of follow‐up assessments in patients with idiopathic pulmonary arterial hypertension;Nickel N;Eur Respir J,2012

4. Clinical worsening in trials of pulmonary arterial hypertension: results and implications;Galiè N;Curr Opin Pulm Med,2010

5. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galiè N;Eur Heart J,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of pulmonary hypertension in special conditions;European Respiratory Journal;2024-08-29

2. Racial disparities in treatment patterns, healthcare resource use, and outcomes in patients with pulmonary arterial hypertension in the United States;Current Medical Research and Opinion;2024-08

3. Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review;European Respiratory Review;2024-07

4. Treatment patterns and factors associated with adherence in pulmonary arterial hypertension;Farmacia Hospitalaria;2024-07

5. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study;Journal of Medical Economics;2024-04-10